Prostate biopsy

Minerva Urologica e Nefrologica

Volumn 55, Issue 4, 2003, Pages 205-218

  Seitz, C ^a   Palermo, S ^a   Djavan, B ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Biopsy, needle; Prostatic neoplasms, diagnosis; Prostatic specific antigen

Indexed keywords

ANTIBIOTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ANTIBIOTIC PROPHYLAXIS; BLEEDING; CANCER GRADING; CANCER LOCALIZATION; CANCER SCREENING; DIGITAL RECTAL EXAMINATION; HUMAN; MALE; MORBIDITY; PHYSICAL EXAMINATION; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; SURGICAL TECHNIQUE; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT INDICATION;

BIOPSY, NEEDLE; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 1542348625     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. US Cancer Statistics Working Group. United States Cancer Statistics. 1999 Incidence Atlanta (GA): Department of health and human services, Center for Disease Control and Prevention and National Cancer Institute 2002.
2. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270:860-4.
3. Djavan B, Susani M, Bursa B, Basharkhah A, Simak R, Marberger M. Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol 1999;5:139-42.
4. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61. Erratum in: N Engl J Med 1991;325:1324.
5. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61. Erratum in: N Engl J Med 1991;325:1324.
6. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992;147:841-5.
7. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994;151:1571-4.
8. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliffe TL et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-20.
9. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542-7.
10. Chen YT, Luderer AA, Thiel RP, Carlson G, Cuny CL, Soriano TF. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology 1996;47:518-24.
11. Djavan B, Zlotta AR, Remzi M, Ghawidel K, Basharkhah A, Schulman CC et al. Optimal predictors of prostate cancer in repeat prostate biopsy: a prospective study in 1 051 men. J Urol 2000;163:1144-8.
12. Djavan B, Zlotta AR, Byttebier G, Shariat S, Omar M, Schulman CC, Marberger M. Prostate specific antigen density of the TZ for early detection of prostate cancer. J Urol 1998;160:411-8.
13. Zlotta AR, Djavan B, Damoun M, Roumeguere T, Petrin M, Entezari K et al. The importance of measuring the prostatic transition zone; an anatomical and radiological study. Br J Urol Int 1999;84:661-6.
14. Chan DW, Sokoll LJ, Partin AW, Wong PY, Sasse E., Montie J et al. The use of % free PSA to predict prostate cancer probabilities: an eleven center prospective study using an automated immunoassay system in a population with nonsuspicious DRE. J Urol 1999;161 (Suppl 4):A353.
15. Horninger W, Reissigl A, Klocker H, Rogatsch H, Fink K, Strasser H et al. Improvement of specificity in PSA-based screening by using PSA transition zone density and percent free PSA in addition to total PSA levels. Prostate 1998;37:133-9.
16. Carter HB, Morell CH, Pearson JD, Brant LJ, Plato CC, Metter EJ et al. Estimation of prostatic growth using serial prostatic specific antigen measurements in men with and without prostatic disease. Cancer Res 1992;52:3323-8.
17. Smith DS, Catalona WJ. Rate of change of serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994;152:1163-7.
18. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995;154:407-13
19. Carter HB, Pearson JD, Metter EJ. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-20.
20. Brawer MK, Beatie, Wener MH. PSA as the initial test in prostate carcinoma screening: Results on the third year. J Urol 1993;149:299A.
21. Mettlin C, Littrup PJ, Kane RA, Murphy GP, Lee F, Chesley A et al. Relative sensitivity and specificity of serum PSA level compared with age-referenced PSA, PSA density and PSA change. Cancer 1994;74:1615-20.
22. Seaman E, Whang M, Olsson CA, Katz A, Cooner WH, Benson MC. PSA density (PSAD). Role in patient evaluation and management. Urol Clin North Am 1993;20:653-63.
23. Bare R, Hart L, McCullough DL. Correlation of prostate-specific antigen and prostate-specific antigen density with outcome of prostate biopsy. Urology 1994;43:191-6.
24. Brawer MK, Aramburu EAG, Chen GL, Preston SD, Ellis WJ. The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol 1993;150:369-73.
25. Orozco R, ODowd GJ, Kunnel B, Miller MC, Veltri RW. Observations on pathology trends in 62,537 protstate biopsies obtained from urology private practices in the United States. Urology 1998;51:186-95.
26. Bostwick DG, Qian J, Frankel K. The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies. J Urol 1995;154:1791-4.
27. Feneley MR, Green J, Young M, Kirby R, Bose P, Peeling WB, Parkinson MC. The prevalence of prostatic intraepithelial neoplasia (PIN) in biopsies from hospital practice and pilot screening: clinical implications. Prostate Cancer Prostatic Dis 1997;1:79-83.
28. Aboseif S, Shinohara K, Weidner N, Narayan P, Carroll PR. The significance of prostatic intra-epithelial neoplasia. Br J Urol 1995;76:355-9
29. Raviv G, Janssen T, Zlotta AR, Descamps F, Verhest A, Schulman CC. Prostatic intraepithelial neoplasia: influence of clinical and pathological data on the detection of prostate cancer. J Urol 1196;156:1050-4; discussion 1054-5.
30. Langer JE, Rovner ES, Coleman BG, Yin D, Arger PH, Malkowicz SB et al. Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy. J Urol 1996;155:228-31. Erratum in: J Urol 1996;156:185.
31. Langer JE, Rovner ES, Coleman BG, Yin D, Arger PH, Malkowicz SB et al. Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy. J Urol 1996;155:228-31. Erratum in: J Urol 1996;156:185.
32. Wills ML, Hamper UM, Partin AW, Epstein JI. Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens. Urology 1997;49:367-73.
33. O'dowd GJ, Miller MC, Orozco R, Veltri RW. Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology 2000;55:553-9.
34. Davidson D, Bostwick DG, Qian J, Wollan PC, Oesterling JE, Rudders RA et al. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J Urol 1995;154:1295-9.
35. Berner A, Danielsen HE, Pettersen EO, Fossa SD, Reith A, Nesland JM. DNA distribution in the prostate. Normal gland, benign and premalignant lesions, and subsequent adenocarcinomas. Anal Quant Cytol Histol 1993;15:247-52.
36. Chan TY, Epstein JI. Follow-up of atypical prostate needle biopsies suspicious for cancer. Urology 1999;53:351-5.
37. Iczkowski KA, Bostwick DG. Prostate biopsy interpretation. Current concepts, 1999. Urol Clin North Am 1999;26:435-52.
38. Uzzo RG, Wei JT, Waldbaum RS, Perlmutter AP, Byrne JC, Vaughan ED Jr. The influence of prostate size on cancer detection. Urology 1995;46:831-6.
39. Karakiewicz PI, Bazinet M, Aprikian AG, Trudel C, Aronson S, Nachabe M et al. Outcome of sextant biopsy according to gland volume. Urology 1997;49:55-9.
40. Vashi AR, Wojno KJ, Gillespie B, Oesterling JE. A model for the number of cores per prostate biopsy based on patient age and prostate gland volume. J Urol 1998;159:920-4.
41. Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995;45:2-12.
42. Billebaud T, Villers A, Astier L, Sibert A, Baron JC, Delnas V et al. Advantage of systematic random ultrasound-guided biopsies, measurement of serum specific antigen levels and determination of prostate volume in the early diagnosis of prostate cancer. Eur Urol 1992;21:6-14.
43. Karakiewicz PI, Aprikian AG, MeshrefAW, Bazinet M. Computer-assisted comparative analysis of four-sector and six section biopsies of the prostate. Urology 1996;48:747-50.
44. Karakiewicz PI, Hanley JA, Bazinet M. Three-dimensional computer-assisted analysis of sector biopsy of the prostate. Urology 1998;52:208-12.
45. Ravery V, Billeband T, Toublanc M, Boccon-Gibod L, Hermien JF, Moulinver F et al. Diagnostic value of the systematic trus-guided prostate biopsies. Eur Urol 1999;35:298-303.
46. Eskew AL, Bare RL, Me Cullongh DL. Systematic 5-region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997;157:199-202.
47. Bauer JJ, Zeng J, Weir J, Zhang W, Sesterhem IA, Connely RR et al. Three-dimensional computer-simulated prostate models: lateral prostate biopsies increase the detection rate of prostate cancer. Urology 1999;53:961-7.
48. Chang JJ, Shinohara K, Bhargava V, Presti JC Jr. Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. J Urol 1998;160:2111-4.
49. Norberg M, Egevad L, Holmberg L, Sparen P, Norien BJ, Busch C. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 1997;50:562-6.
50. Djavan B, Zlotta AR, Ekane S, Remzi M, Kramer G, Roumeguere T et al. Is one set of sextant biopsies enough to rule out prostate cancer? Influence of transition and total prostate volumes on prostate cancer yield. Eur Urol 2000;38:218-24.
51. Chen ME, Troncoso P, Johnston DA, Tang K, Babaian RJ. Optimization of prostate biopsy strategy using computer based analysis. J Urol 1997;158:2168-75.
52. Djavan B, Zlotta AR, Remzi M, Bursa B, Hruby S, Wolfram R et al. Total and transition zone prostate volume and age: How do they affect the utility of PSA based diagnostic parameters for early prostate cancer detection? Urology 1999;54:846-52.
53. Zlotta AR, Djavan B, Marberger M, Schulmann CC. Prostate specific antigen density of the transition zone: A new effective parameter for prostate cancer prediction. J Urol 1997;157:1315-21.
54. Levine MA, Ittman M, Melamed J, Lepor H. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol 1998;159:471-6.
55. Letran JL, Meyer GE, Loberiza FR, Brawer MK. The effect of prostate volume on the yield of needle biopsy. J Urol 1998;160:1718-21.
56. Djavan B, Remzi M, Seitz C, Anagnostou T, Dobrovits M, Harik M et al. The Vienna Nomograms: a novel biopsy strategy defining the optimal number of cares base on PSA, age and prostate volume. J Urol 2003;169:119. (abstract 462).
57. Carey JM, Korman HJ. Transrectal ultrasound guided biopsy of the prostate. Do enemas decrease clinically significant complications? J Urol 2001;166:82-5.
58. Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ et al. Prostate cancer detection in a clinical urological practice by ultrasonography. Digital rectal examination and prostate specific antigen. J Urol 1990;143:1146-52; discussion 1152-4.
59. Rodríguez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. J Urol 1998;160:2115-20.
60. Kapoor DA, Klimberg IW, Malek GH, Wegenke JD, Cox CE, Patterson AL et al. Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology 1998;52:552-8.
61. Clements R, Aideyan OU, Griffiths GJ, Peeling WB. Side effects and patient acceptability of transrectal biopsy of the prostate. Clin Radiol 1993;47:125-6.
62. Collins GN, Lloyd SN, Hehir M, McKelvie GB. Multiple transrectal ultrasound-guided prostatic biopsies-true morbidity and patient acceptance. Br J Urol 1993;71:460-3.
63. Nash PA, Bruce JE, Indudhara R, Shinohara K. Transrectal ultrasound guided prostatic nerve blockade eases systematic needle biopsy of the prostate. J Urol 1996;155:607-9.
64. Issa MM, Bux S, Chun T, Petros JA, Labadia AJ, Anastasia K. et al. A randomized prospective trial of intrarectal lidocaine for pain control during transrectal prostate biopsy: the Emory University experience. J Urol 2000;164:397-9.
65. Alavi AS, Soloway MS, Vaidya A, Lynne CM, Gheiler EL. Local anesthesia for ultrasound guided prostate biopsy: a prospective randomized trial comparing 2 methods. J Urol 2001;166:1343-5.
66. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997;157:199-202; discussion 202-3.
67. Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001;166:86-91; discussion 91-2.
68. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989;142:71-4; discussion 74-5.
69. Presti JR, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 2000;163:163-7.
70. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma: correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988;12:897-906.
71. Bazinet M, Karakiewicz PI, Aprikian AG, Trudel C, Aronson S, Mechabe M et al. Value of systematic TZ biopsies in the early detection of prostate cancer. J Urol 1996;155:605-6.
72. Terris MK, Pham TQ, Issa MM, Kabalin JN. Routine TZ and seminal vesicle biopsies in all patients undergoing transrectal ultrasound giuded prostate biopsies are not indicated. J Urol 1997;157:204-6.
73. Morote J, Lopes M, Encabo G, de Torres I. Value of routine TZ biopsies in patientes undergoing ultrasound-guided sextant biopsies for the first time. Eur Urol 1999:35:294-7.
74. Epstein JI, Walsh PC, Sauvageot J, Carter HB. Use of repeat sextant and transistion zone biopsies for assessing extent of prostate cancer. J Urol 1997;158:1886-90.
75. Levine MA, Ittman M, Melamed J, Lepor H. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol 1998;159:471-5; discussion 475-6.
76. Eskew LA, Woodruff RD, Bare RL, McCullough DL. Prostate cancer diagnosed by the 5 region biopsy method is significant disease. J Urol 1998;160:794-6.
77. Chan TY, Chan DY, Lecksell K, Stutzman RE, Epstein JI. Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors? J Urol 2001;166:2181-4.
78. Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000;163:152-7.
79. Rietbergen, JBW, Kruger, AE, Hoedemaeker, RF, Bangma, CH, Kirkels, WJ, Schröder, FH. Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer. J Urol 1998;160:2121-5.
80. Fowler JE Jr, Bigler SA, Miles D, Yalkut DA. Predictors of first repeat biopsy cancer detection with suspected local prostate cancer. J Urol 2000;163:813-8.
81. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999;281:1395-400.
82. Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M et al. Prospective evaluation of cancers detected on biopsies: 1, 2, 3 and 4. When should we stop? J Urol 2002;168-200.
83. Bazinet M, Karakiewicz PI, Aprikian AG, Trudel C, Aronson S, Nachabé M et al. Value of systematic transition zone biopsies in the early detection of prostate cancer. J Urol 1996;155:605-6.
84. Terris MK, Pham TQ, Issa MM, Kabalin JN. Routine transition zone and seminal vesicle biopsies in all patients undergoing transrectal ultrasound guided prostate biopsies are not indicated. J Urol 1997;157:204-6.
85. Fleshner NE, Fair WR. Indications for transition zone biopsy in the detection of prostatic carcinoma. J Urol 1997;157:556-8.
86. Keetch DW, Catalona WJ. Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostatic specific antigen values. J Urol 1995;154:1795-7.
87. Lui PD, Terris MK, McNeal JE, Stamey TA. Indications for ultrasound guided transition zone biopsies in the detection of prostate cancer. J Urol 1995;153:1000-3.
88. Brullet E, Guevara MC, Campo R, Falco J, Puig J, Prera A et al. Massive rectal bleeding following transrectal ultrasound-guided prostate biopsy. Endoscopy 2000;32:792-5.
89. Stricker HJ, Ruddock LJ, Wan J, Belville WD. Detection of non-palpable prostate cancer. A mathematical and laboratory model. Br J Urol 1993;71:43-6.
90. Applewhite JC, Matlaga BR, McCullough DL. Results of the 5 region prostate biopsy method: the repeat biopsy population. J Urol 2002;168:500-3.
91. Sieber PR, Rommel, Augusta, Breslin JA, Huffnagle HW, Harpster LE. Antibiotic prophylaxis in ultrasound guided prostate biopsy. J Urol 1997;157:2199-200.